Literature DB >> 22344676

Carvedilol attenuates oxidative stress in chronic chagasic cardiomyopathy.

Patrícia Budni1, Roberto Coury Pedrosa, Thais Regina Garlet, Eduardo Monguilhott Dalmarco, Juliana Bastos Dalmarco, Manuel Rosa de Oliveira Lino, Edésio Luiz Simionato, Jorge Antônio Amara, Tânia Sílvia Frode, Danilo Wilhelm Filho.   

Abstract

BACKGROUND: There is increasing evidence suggesting that Chagas disease involves oxidative damage and contributes to heart disease progression.
OBJECTIVE: To evaluate the effect of carvedilol on oxidative stress markers in chronic Chagas disease.
METHODS: The study population included 42 patients with Chagas cardiomyopathy and oxidative stress biomarkers were measured before and after a period of six months of treatment with carvedilol (37.5 mg/day). Patients were considered according to the Los Andes classification and the activity of superoxide dismutase, catalase, glutathione peroxidase, S-transferase and reductase, myeloperoxidase and adenosine deaminase; levels of reduced glutathione, thiobarbituric acid reactive species, carbonyl protein, vitamin E and nitric oxide were measured in blood.
RESULTS: After treatment with carvedilol, all groups showed significant reductions in levels of carbonyl protein and reduced glutathione, whereas the levels of nitric oxide and adenosine activity increased significantly only in group IA. Moreover, most of the antioxidant enzymes showed decrease in activity in groups IA and IB.
CONCLUSION: The data suggest that treatment with carvedilol was effective in attenuating oxidative damage, an effect that may be particularly important in patients with chronic Chagas' disease cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22344676     DOI: 10.1590/s0066-782x2012005000015

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  7 in total

1.  Carvedilol enhances the antioxidant effect of vitamins E and C in chronic Chagas heart disease.

Authors:  Patrícia Budni; Roberto Coury Pedrosa; Eduardo Monguilhott Dalmarco; Juliana Bastos Dalmarco; Tânia Sílvia Frode; Danilo Wilhelm Filho
Journal:  Arq Bras Cardiol       Date:  2013-09-06       Impact factor: 2.000

2.  Immunopharmacological approach of carvedilol in chronic Chagas heart disease.

Authors:  Carla Paixão Miranda; Fernando Antônio Botoni; Manoel Otávio da Costa Rocha
Journal:  Arq Bras Cardiol       Date:  2014-10       Impact factor: 2.000

3.  Clinical predictors of inducible sustained ventricular tachycardia during electrophysiologic study in patients with chronic Chagas' heart disease.

Authors:  Augusto Cardinalli-Neto; Adalberto M Lorga-Filho; Elissandro F Silva; Renata P Lima; Eduardo Palmegiani; Reinaldo B Bestetti
Journal:  Int J Cardiol Heart Vasc       Date:  2015-10-19

4.  Potential Role of Carvedilol in the Cardiac Immune Response Induced by Experimental Infection with Trypanosoma cruzi.

Authors:  Aline Luciano Horta; Ana Luisa Junqueira Leite; G Paula Costa; Vivian Paulino Figueiredo; André Talvani
Journal:  Biomed Res Int       Date:  2017-03-09       Impact factor: 3.411

Review 5.  Potential Role of Antioxidants as Adjunctive Therapy in Chagas Disease.

Authors:  Juana P Sánchez-Villamil; Paula K Bautista-Niño; Norma C Serrano; Melvin Y Rincon; Nisha J Garg
Journal:  Oxid Med Cell Longev       Date:  2020-03-26       Impact factor: 6.543

6.  Antioxidant effect of Morus nigra on Chagas disease progression.

Authors:  Michelly Cristina Montenote; Vithor Zuccaro Wajsman; Yoichi Takaki Konno; Paulo César Ferreira; Regildo Márcio Gonçalves Silva; Altino Luiz Silva Therezo; Luciana Pereira Silva; Luciamáre Perinetti Alves Martins
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-11-06       Impact factor: 1.846

7.  The β-blocker carvedilol and the benznidazole modulate the cardiac immune response in the acute infection induced by Colombian strain of the Trypanosoma cruzi.

Authors:  Aline Luciano Horta; Vivian Paulino Figueiredo; Ana Luisa Junqueira Leite; Guilherme de Paula Costa; Ana Paula de Jesus Menezes; Camila de Oliveira Ramos; Tamiles Caroline Fernandes Pedrosa; Frank Silva Bezerra; Paula Melo de Abreu Vieira; André Talvani
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-10-18       Impact factor: 2.743

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.